Sana Biotechnology (NASDAQ:SANA) Shares Down 6.2% – What’s Next?

Posted by George Bondi on Aug 22nd, 2026

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report)’s stock price was down 6.2% on Thursday . The company traded as low as $3.84 and last traded at $3.8450. Approximately 306,599 shares traded hands during trading, a decline of 90% from the average session volume of 3,117,871 shares. The stock had previously closed at $4.10.

Wall Street Analyst Weigh In

SANA has been the topic of a number of recent analyst reports. Bank of America decreased their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.33.

Read Our Latest Report on SANA

Sana Biotechnology Stock Up 4.5%

The firm has a 50 day moving average of $3.47 and a two-hundred day moving average of $3.42. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -5.14 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Sell-side analysts forecast that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors have recently added to or reduced their stakes in SANA. Walleye Capital LLC bought a new position in Sana Biotechnology in the 2nd quarter valued at approximately $35,000. Royal Bank of Canada boosted its position in Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after buying an additional 5,338 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the third quarter worth $36,000. Rockefeller Capital Management L.P. grew its stake in shares of Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after buying an additional 4,088 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Sana Biotechnology during the third quarter worth $39,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.